Abstract
Currently rational drug design is limited to using protein targets in the design and production of therapeutic agents. However, many genetic and infectious diseases may not be adequately treated with this approach. In these circumstances the DNA sequence of an offending gene is itself a potential target for rational drug development. Genetargeted therapeutic strategies require the development of ligands that can recognize and bind unique DNA targets sequence specifically. Several approaches have been described for the development of sequence-specific DNA targeting agents. These include synthetic polyamides that recognize and bind to DNA in the minor groove, peptide nucleic acids which can penetrate the DNA duplex and form a P-loop, or a triple-helical structure with one of its strands, and triplehelix (triplex) forming oligonucleotides which bind to the major groove of duplex DNA at polypyrimidine / polypurine sequences. Of these, Triplex-Forming Oligonucleotides (TFOs) are the most extensively characterized synthetic ligands capable of recognizing and binding sequence specifically to duplex DNA. Consequently, they have been the focus of a new gene therapy strategy that we call ‘anti-gene radiotherapy’. This strategy employs TFOs labeled with Auger-electronemitting radionuclides to produce sequence-specific DNA double strand breaks that ultimately lead to gene inactivation following repair. Anti-gene radiotherapy is made possible by the highly localized damage produced by decay of an Augeremitter, such as 125I, and the sequence specific positioning of DNA damage made possible by TFOs. This report will address recently described strategies that employ these gene-targeting methods to alter target gene expression or structure, with particular emphasis being paid to the use of TFOs in anti-gene radiotherapy.
Keywords: gene-targeted agents, anti-gene radio therapy, triplex-forming oligonucleotide, tfos
Current Genomics
Title: Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy
Volume: 4 Issue: 3
Author(s): Thomas A. Winters, Elzbieta Pastwa, Kamal Datta and Ronald D. Neumann
Affiliation:
Keywords: gene-targeted agents, anti-gene radio therapy, triplex-forming oligonucleotide, tfos
Abstract: Currently rational drug design is limited to using protein targets in the design and production of therapeutic agents. However, many genetic and infectious diseases may not be adequately treated with this approach. In these circumstances the DNA sequence of an offending gene is itself a potential target for rational drug development. Genetargeted therapeutic strategies require the development of ligands that can recognize and bind unique DNA targets sequence specifically. Several approaches have been described for the development of sequence-specific DNA targeting agents. These include synthetic polyamides that recognize and bind to DNA in the minor groove, peptide nucleic acids which can penetrate the DNA duplex and form a P-loop, or a triple-helical structure with one of its strands, and triplehelix (triplex) forming oligonucleotides which bind to the major groove of duplex DNA at polypyrimidine / polypurine sequences. Of these, Triplex-Forming Oligonucleotides (TFOs) are the most extensively characterized synthetic ligands capable of recognizing and binding sequence specifically to duplex DNA. Consequently, they have been the focus of a new gene therapy strategy that we call ‘anti-gene radiotherapy’. This strategy employs TFOs labeled with Auger-electronemitting radionuclides to produce sequence-specific DNA double strand breaks that ultimately lead to gene inactivation following repair. Anti-gene radiotherapy is made possible by the highly localized damage produced by decay of an Augeremitter, such as 125I, and the sequence specific positioning of DNA damage made possible by TFOs. This report will address recently described strategies that employ these gene-targeting methods to alter target gene expression or structure, with particular emphasis being paid to the use of TFOs in anti-gene radiotherapy.
Export Options
About this article
Cite this article as:
Winters A. Thomas, Pastwa Elzbieta, Datta Kamal and Neumann D. Ronald, Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy, Current Genomics 2003; 4 (3) . https://dx.doi.org/10.2174/1389202033490420
DOI https://dx.doi.org/10.2174/1389202033490420 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews Pictorial US, CT and MRI Findings of Common Hepatic Tumours
Current Medical Imaging Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications
Current Cancer Drug Targets Inhibition of Bacterial Carbonic Anhydrases and Zinc Proteases: From Orphan Targets to Innovative New Antibiotic Drugs
Current Medicinal Chemistry The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Role of Polyamines in Breast Cancer Growth, Development and Progression
Current Cancer Therapy Reviews Nuclear Imaging of Prostate Cancer with Gastrin-Releasing-Peptide- Receptor Targeted Radiopharmaceuticals
Current Pharmaceutical Design The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Spectrum of Unusual Imaging Findings of Metastatic Lesions from Gastric Cancer
Current Medical Imaging Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery A Review of the Effects of Gold, Silver, Selenium, and Zinc Nanoparticles on Diabetes Mellitus in Murine Models
Mini-Reviews in Medicinal Chemistry Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued)